| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/31/2002 | EP1227098A1 Triazolopurine derivatives, drug compositions containing the same and adenosine a3 receptor affinitive agents |
| 07/31/2002 | EP1227095A2 A process for the purification of (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5yl)-methyl)-2-oxazolidinone |
| 07/31/2002 | EP1227092A2 Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1227091A2 Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1227088A1 Crystalline base of citalopram and hydrochoride or hydrobromide salt thereof |
| 07/31/2002 | EP1226822A2 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same |
| 07/31/2002 | EP1226441A1 Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies |
| 07/31/2002 | EP1226435A1 Axor35, a g-protein coupled receptor |
| 07/31/2002 | EP1226276A2 Diagnostic test for cephalic pain |
| 07/31/2002 | EP1226252A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226251A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 07/31/2002 | EP1226249A2 Follistatin-related protein zfsta4 |
| 07/31/2002 | EP1226247A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 07/31/2002 | EP1226246A1 Polypeptides with expanded primary signalling motifs |
| 07/31/2002 | EP1226245A2 Hybrid adaptor receptors |
| 07/31/2002 | EP1226244A2 Polypeptides with non-natural primary signalling motifs |
| 07/31/2002 | EP1226243A2 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 07/31/2002 | EP1226239A1 Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| 07/31/2002 | EP1226170A2 Human proteins and polynucleotides encoding the same |
| 07/31/2002 | EP1226160A2 Novel antiarrhythmic peptides |
| 07/31/2002 | EP1226159A1 Substituted dipeptides having nos inhibiting activity |
| 07/31/2002 | EP1226155A2 18-nor-steroids as selectively active estrogens |
| 07/31/2002 | EP1226152A2 Regulation of gene expression by neuroleptic agents |
| 07/31/2002 | EP1226148A2 Novel oligosaccharides, preparation method and pharmaceutical compositions containing same |
| 07/31/2002 | EP1226143A2 Imidazopyridine derivatives used as phosphodiesterase vii inhibitors |
| 07/31/2002 | EP1226141A1 Heterocyclic substituted pyrazolones |
| 07/31/2002 | EP1226139A2 Cyclized amide derivatives for treating or preventing neuronal damage |
| 07/31/2002 | EP1226137A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 07/31/2002 | EP1226133A2 N-SUBSTITUTED 3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES AND 1,4-THIOBUTYROLACTONES FOR USE AS PROMOTER OF $g(g)-AMINOBUTYRIC ACID ACTIVITY AND FOR TREATING NERVOUS DISORDERS AND PREPARATION METHOD |
| 07/31/2002 | EP1226132A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
| 07/31/2002 | EP1226131A2 Isoxazolecarboxamide derivatives |
| 07/31/2002 | EP1226126A1 Pyrimidine derivatives |
| 07/31/2002 | EP1226124A1 Heterocyclically substituted benzoylguanidine, method for the production thereof, the use thereof as a medicament or means of diagnosis and a medicament containing the same |
| 07/31/2002 | EP1226121A1 Method of inhibiting neurotrophin-receptor binding |
| 07/31/2002 | EP1226120A2 Benz[f]indoles for use in the treatment of 5ht receptor related disorders |
| 07/31/2002 | EP1226115A1 Novel carbamates and ureas |
| 07/31/2002 | EP1226112A2 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 07/31/2002 | EP1226110A1 Bicyclic amino acids as pharmaceutical agents |
| 07/31/2002 | EP1226108A1 Diaryl-enynes |
| 07/31/2002 | EP1225955A1 Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
| 07/31/2002 | EP1225951A2 A dual adhesive transdermal drug delivery system |
| 07/31/2002 | EP1225900A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 07/31/2002 | EP1225894A1 Fab i inhibitors |
| 07/31/2002 | EP1225888A2 Sustained-release formulations for treating cns-mediated disorders |
| 07/31/2002 | EP1225886A2 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| 07/31/2002 | EP1225884A1 Method for administering a phosphodiesterase 4 inhibitor |
| 07/31/2002 | EP1225880A2 Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| 07/31/2002 | EP1225877A2 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 07/31/2002 | EP1042310B1 Method for the preparation of citalopram |
| 07/31/2002 | EP1009750B1 Novel (alpha-aminophosphino) peptide derivatives, method for making same and therapeutic applications thereof |
| 07/31/2002 | EP0920630B1 Prion binding proteins and uses thereof |
| 07/31/2002 | EP0914115A4 Methods of providing neuroprotection |
| 07/31/2002 | EP0824356B1 Pharmaceutical compositions for the treatment of alcohol addiction |
| 07/31/2002 | EP0817969B1 Inhibition of tau-tau-association |
| 07/31/2002 | EP0764152B1 Substituted indolylmethylene-oxindole analogues as tyrosine kinase inhibitors |
| 07/31/2002 | EP0755930B1 Benzoxazepine derivatives, salts thereof, and drugs containing the same |
| 07/31/2002 | EP0755398B1 Process for the resolution of etodolac using glucamine derivatives |
| 07/31/2002 | CN1361783A Thiazoloderivatives and pharmaceutical compositions containing them |
| 07/31/2002 | CN1361782A Substituted imidazothiazoles as antidepressant agents |
| 07/31/2002 | CN1361781A Oxazinocarbazoles for the treatment of CNS diseases |
| 07/31/2002 | CN1361780A Purine derivatives, preparation method and pharmaceutical compositions containing same |
| 07/31/2002 | CN1361779A New compounds |
| 07/31/2002 | CN1361776A Novel fluorinated imidazoline Benzodioxane, preparation and therapeutic uses thereof |
| 07/31/2002 | CN1361774A Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 07/31/2002 | CN1361773A Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/31/2002 | CN1361768A Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| 07/31/2002 | CN1361698A Prolyl endopeptidase inhibitor |
| 07/31/2002 | CN1361695A Analgesic from snake venom |
| 07/31/2002 | CN1361692A Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts |
| 07/31/2002 | CN1361691A New use of a macrolide compound |
| 07/31/2002 | CN1361690A Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 07/31/2002 | CN1360893A Sobering-up liver-protecting compound prepn |
| 07/31/2002 | CN1360855A Multielement calcium-rich liver-protecting sobering up beverage |
| 07/31/2002 | CN1088460C Process for isolating galanthamine |
| 07/31/2002 | CN1088459C 1,4-disubstituted piperazines |
| 07/31/2002 | CN1088456C Substituted oxazolidine calpain and/or cathepsin B inhibitors |
| 07/31/2002 | CN1088359C Medicine for curing cerebrovascular disturbance with psychonosema |
| 07/31/2002 | CA2369462A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of pde4 isozymes |
| 07/30/2002 | US6426422 Method for the preparation of citalopram |
| 07/30/2002 | US6426413 Inhibitors of caspases |
| 07/30/2002 | US6426405 Therapeutic target for treatment of diseases associated with altered muscle activity of pain transmission; has properties of glycine transporter associated with strychnine sensitive glycine receptors--properties called ?sc6? activity |
| 07/30/2002 | US6426368 Method for preventing and treating alcoholism |
| 07/30/2002 | US6426364 Nervous system or psychological disorders |
| 07/30/2002 | US6426350 Alpha-2 adrenoceptor antagonists; use treating nervous system disorders |
| 07/30/2002 | US6426347 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands |
| 07/30/2002 | US6426344 Aryl and heteroaryl substituted indolealkanoic acids |
| 07/30/2002 | US6426343 Preparation and use of a specific GABA-Aα5 receptor ligand for treatment of Alzheimer's disease |
| 07/30/2002 | US6426341 Treatment for diabetic complications |
| 07/30/2002 | US6426199 Isolated, purified nucleic acid detecting or isolating mutant forms of the dna molecules. |
| 07/30/2002 | US6426068 Prevent cell or organ degradation; plant extracts |
| 07/30/2002 | CA2344707C N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives |
| 07/30/2002 | CA2291067C Method for the preparation of citalopram |
| 07/30/2002 | CA2104461C Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same |
| 07/30/2002 | CA2067614C Agent for improving dementia |
| 07/30/2002 | CA2039052C Process for preparing piroxicam/cyclodextrin complexes, the products obtained and their pharmaceutical compositions |
| 07/25/2002 | WO2002058323A2 Method for identifying modulators of bace |
| 07/25/2002 | WO2002057778A1 Screening assay for cotranslational translocation interfering compounds |
| 07/25/2002 | WO2002057484A2 Method and test system for identifying substances which protect nerve cells |
| 07/25/2002 | WO2002057483A2 Method of identifying modulators of nogo-functions |
| 07/25/2002 | WO2002057460A2 Polynucleotides encoding human phosphatases |